INTRODUCTION {#S2}
============

The RASopathy neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant genetic disorders. *NF1* gene mutation, alone or with subsequent loss of the previously normal somatic allele, can lead to a variety of conditions in NF1 patients, ranging from aesthetic issues such as epidermal hyperpigmentation, to disabling bone malformations and aggressive life-threatening tumors ([@R45]). NF1-associated neurological abnormalities include learning deficits, delayed acquisition of motor skills, and attention-deficit disorder, with or without hyperactivity; autism manifestations may also be present ([@R1]; [@R24]). Cognitive dysfunction is the most common complication affecting the quality of life of children and adolescents with NF1 ([@R28]), many of whom require neuropsychological assessment for educational planning ([@R2]).

Significant advances have been made toward understanding how *Nf1* mutation impacts neurons, and treatments to ameliorate neuronal abnormalities have been proposed. In animal models, activity of hippocampal interneurons ([@R18]) and dopaminergic neurons ([@R19]) are affected by *Nf1* mutation. Notably, correlated abnormal behaviors are rescued by treatment with statins ([@R36]) and dopamine re-uptake inhibitors ([@R9]), respectively. Nevertheless, mixed results in clinical studies ([@R5]; [@R50], [@R51]), along with possible memory-associated side effects ([@R48]), have precluded definitive recommendation of the use of statins in NF1 patients. Therefore, better understanding of molecular mechanisms underlying NF1 neurological issues is crucial to establish successful treatment regimens.

In addition to neuronal defects, 60%--70% of children with NF1 show white matter (WM) abnormalities, including enlarged brain WM tracts, T2 hyperintensities, and altered fractional anisotropy and diffusivity on diffusion tensor imaging (DTI) ([@R33]; [@R44]). Myelin produced by mature oligodendrocytes (mOLs) increases nerve impulse velocity; thus, normal brain function requires normal myelin and oligodendrocyte function ([@R23]). Indeed, learning and motor skill acquisition correlate with changes in WM and myelin ([@R40]). Nonetheless, research on effects of *Nf1* loss in mOLs is limited. We reported nitric oxide (NO)-mediated myelin decompaction \>1 year after *Nf1* inactivation, correlating with decreased tight junction (TJ) and GAP-junction (GJ) proteins ([@R39]). However, what signaling pathways cause these phenotypes and whether loss of *Nf1* in oligodendrocytes causes behavioral changes is unknown.

Nf1 is a RAS GTPase-activating protein, so that loss of *Nf1* results in increased RAS-mitogen-activated protein kinase (MAPK) signaling ([@R45]). RAS and Notch pathways can cooperate or antagonize each other in a context-dependent manner. Although Notch acts downstream of Nf1 during differentiation of neural stem cells ([@R13]), no links between these pathways have been described in mOL. Here, we show genetic and pharmacological evidence indicating that Notch signaling controls progressive and *Nf1* gene-dose-dependent myelin defects in the corpus callosum (CC) of *PlpCre*^ER^*;Nf1*^flox^ animals. Abnormal behavior in hemizygous mutants is rescued by pharmacological inhibition of Notch. Mechanistically, aberrant Notch activation and myelin defects are rescued by inhibition of NO signaling, revealing NO as a crucial link between RAS and Notch pathways. Increased activation of Notch is also found in *Nf1*^+/−^ mice and in WM of NF1 patients, suggesting that abnormal Notch signaling is a feature of NF1.

RESULTS {#S3}
=======

*Nf1* Loss in mOLs Causes *Nf1* Gene-Dose-Dependent Progressive Myelin Decompaction {#S4}
-----------------------------------------------------------------------------------

We previously reported that myelin decompaction occurs in the optic nerve (ON) 6--12 months after tamoxifen-induced deletion of *Nf1* in Plp1-expressing mOLs ([@R39]). To study whether *Nf1* loss-dependent myelin defects occur in the brain and their progression, we analyzed the CC of adult tamoxifen-treated homozygous (*PlpCre*^ER^*;Nf1*^flox/flox^, henceforth *pNf1f*/*f*) and hemizygous (*PlpCre*^ER^*;Nf1*^flox/+^, henceforth *pNf1f*/+) *Nf1* mutant mice and wild-type (WT) animals (*Nf1*^flox^ or *PlpCre*^ER^), using electron microscopy ([Figures 1A and 1B](#F1){ref-type="fig"}). Unbiased counting of myelinated axons showed no significant differences in g-ratio of control animals between 1 and 8 months after tamoxifen treatment ([Figures S1A and S1C](#SD1){ref-type="supplementary-material"}). Significantly decreased g-ratio in *Nf1* hemizygous mutants, as compared to WTs, was detected at 1 month with a further decrease 6 months post-tamoxifen, indicating progressive changes in fiber structure. In contrast, in homozygous *Nf1* mutants, decreased g-ratio occurred within 1 month post-tamoxifen, and showed slight but significant recovery by 6 months post-tamoxifen ([Figures S1A and S1C](#SD1){ref-type="supplementary-material"}). At this time point, the density of EGFP reporter-positive recombined cells did not differ between WT and *Nf1* mutants ([Figures S1F and S1G](#SD1){ref-type="supplementary-material"}). Although *Nf1* may recombine with different efficiency than EGFP, this result suggests that the trend toward recovery is not due to a depletion of mutant cells. Both parameters determining g-ratio were affected by *Nf1* loss in mOLs; *pNf1* mutants showed increased myelin thickness due to decompaction at intraperiod lines (number of myelin lamellae remained unchanged, [Figures 1B](#F1){ref-type="fig"} and [S1B](#SD1){ref-type="supplementary-material"}) and decreased axon diameter ([Figure S1E](#SD1){ref-type="supplementary-material"}). The latter is likely secondary to disturbed myelin integrity ([@R16]; [@R17]), because neurons with axons in the CC do not express the *PlpCre* allele ([@R34]; [@R39]).

Regions of decompacted myelin were evident in hemizygous and homozygous *pNf1* mutants 1 month post-tamoxifen, albeit to different extents ([Figures 1A](#F1){ref-type="fig"}, insets, and [1B](#F1){ref-type="fig"}). Decompacted fibers among total fibers were quantified. Additionally, severity of decompaction was reflected by the number of quadrants around each axon showing decompaction ([Figure 1C](#F1){ref-type="fig"}, color code). Control animals show baseline myelin "decompaction" ([Figure 1C](#F1){ref-type="fig"}, 1--2 quadrants) in the short- (ST, 1 month) and long-term (LT, 6--9 months) post-tamoxifen treatment, likely indicating cross-sections through paranodal loops and Schmidt-Lanterman incisures. One month post-tamoxifen, *pNf1f*/+ mutants show decompaction in 1--3 quadrants, but not significant total decompaction, while *pNf1f*/*f* show significantly increased total decompacted fibers in 1--4 quadrants, as compared to WTs. Confirming a progressive phenotype, by 6--8 months post-tamoxifen significantly increased decompaction was also detected in hemizygous mice ([Figure 1C](#F1){ref-type="fig"}). Thus, myelin decompaction in the CC is *Nf1* gene-dose-dependent and progressive.

*Nf1* Regulates Myelin Compaction through RAS-MAPK Pathway Activation {#S5}
---------------------------------------------------------------------

To define the mechanisms responsible for myelin decompaction in the CC of *Nf1* mutants, we first analyzed RAS/MAPK pathway activation, which results in phosphorylation and activation of ERK1/2 (pERK). The WT CC showed pERK immunostaining in rare, mainly CC1^−^ cells ([Figure 1D](#F1){ref-type="fig"}). Consistent with activation of MAPK signaling in *Nf1* mutants, increased faint pERK signals were observed in CC1^+^ mOLs of *pNf1f*/+ mice and strong pERK signals in *pNf1f*/*f* mice, at time points when severe decompaction is observable. Quantitative analysis confirmed significantly increased pERK^+^;CC1^+^ mOLs in *pNf1f*/*f* mice 1 month post-tamoxifen, as compared to controls, while a trend toward increase was detected in *pNf1f*/+ mice ([Figure 1E](#F1){ref-type="fig"}). Other signal pathways could cause myelin decompaction in *pNf1f*/+ mutants, and/or modestly increased pERK could cause decompaction in the long-term; if so, decompaction should be sensitive to inhibition of MEK, the ERK kinase. At 9 months post-tamoxifen when myelin decompaction is detectable, we treated *Nf1* hemizygous mutants for 21 days with PD0325901, a brain penetrant MEK inhibitor (MEKi, 1.5 mg/kg). At this therapeutically relevant dose ([@R4]), MEKi fully rescued myelin decompaction ([Figure 1C](#F1){ref-type="fig"}) and g-ratio ([Figure S1D](#SD1){ref-type="supplementary-material"}) in *pNf1f*/+ mice. In fact, myelin was more compacted than WTs, suggesting that basal MAPK signaling contributes to the maintenance of normal compact myelin structure. In homozygous *Nf1* mutants, MEKi improved the severity of decompaction (quadrants) and significantly increased g-ratio, but failed to fully rescue these parameters ([Figures 1C](#F1){ref-type="fig"} and [S1D](#SD1){ref-type="supplementary-material"}), perhaps because the treatment did not abolish abnormal MAPK signaling. In support of this hypothesis, while MEKi significantly decreased pERK^+^;CC1^+^ mOLs, they remained significantly increased in *pNf1f*/*f* mice as compared to controls ([Figures S2A and S2B](#SD1){ref-type="supplementary-material"}). Thus, MAPK signaling contributes to the aberrant myelin compaction in *Nf1* mutants, but a clinically relevant dose of MEKi is insufficient to rescue cells with complete *Nf1* loss of function.

*Nf1* Loss Increases Notch Pathway Activity in Glial Cells In Vitro and In Vivo {#S6}
-------------------------------------------------------------------------------

As in a previous study ([@R39]), WT and mutants showed similar MBP expression around CC1^+^ cells ([Figure S2C](#SD1){ref-type="supplementary-material"}). We aimed to identify other molecules/pathways downstream ERK activation that influence cell signaling and myelin defects following *Nf1* loss. We postulated that transcriptional changes might underlie *Nf1*-loss effects, as MAPK signaling regulate gene expression ([@R30]). Using microarray gene expression analysis of glia-enriched cultures ([@R6]), we identified genes with significantly altered expression in *Nf1*^−^/^−^ as compared to WT cultures. Interestingly, *Hes5*, a direct transcriptional target of canonical Notch signaling, was the most upregulated gene in *Nf1* mutant cells, and other Notch-related genes *(Dll1* and *Dll3*) were also significantly increased, as validated by qRT-PCR ([Figure 2A](#F2){ref-type="fig"}). Upon ligand binding, a cleaved Notch intracellular domain (NICD) is generated, correlating with Notch activation. NICD detection by western blot increased in *Nf1*^−^/^−^ as compared to WT cultures ([Figure 2B](#F2){ref-type="fig"}). To verify these results in vivo in an OL-enriched population, we performed RNA sequencing (RNA-seq) transcriptome analysis using WT and *pNf1f*/*f* optic nerves, 1 month post-tamoxifen. We identified significant increases in transcripts encoding the Notch targets *Hes5*, *Cntnap2*, and *Cttnbp2* ([@R41]). Transcripts encoding Notch ligands also increased (*Dll1*, *Dlk2*, *Dner*, and *Cntn1*) or decreased (*Thbs1*, *Postn*, and *Jag*1). Transcripts encoding GJ and TJ proteins expressed in the oligodendrocyte-lineage, including *Claudin 11*, were also significantly decreased ([Figure 2C](#F2){ref-type="fig"}). To test whether loss of *Nf1* in mOLs increases Notch activation in vivo, we analyzed *Nf1* mutants carrying the transgene *Hes5GFP*, a reporter of canonical Notch pathway activation that is not expressed significantly in normal mOLs. WT animals and *Nf1* mutants contained, as expected, *Hes5GFP*^+^;GFAP^+^ astrocytes ([Figure S3A](#SD1){ref-type="supplementary-material"}) and rare *Hes5GFP*^+^;CC1^+^ mOLs in the CC ([Figure 2D](#F2){ref-type="fig"}, insets). Although Hes5GFP^+^ mOLs were significantly increased in *pNf1f*/*f* animals as compared to WT animals ([Figures 2E](#F2){ref-type="fig"} and [S4E](#SD1){ref-type="supplementary-material"}), they accounted for only 1.41% ± 0.20% of CC1^+^ cells in the CC, and Hes5GFP signal did not overlap with pERK^+^CC1^+^ mOLs ([Figure S3B](#SD1){ref-type="supplementary-material"}).

Hes5 is one of many Notch effectors. To test whether other Notch effectors are likely to be activated in mOLs after loss of *Nf1*, we analyzed NICD immunoreactivity using a specific antibody (aNOTCH). WT mice showed aNOTCH cytoplasmic signals in rare CC1^+^ mOLs. Significantly increased numbers of aNOTCH^+^(nuclear);CC1^+^ mOLs were detected in *pNf1f*/*f* animals ([Figures 2D and 2F](#F2){ref-type="fig"}), corroborating *Nf1* loss-driven, abnormal, Notch activation. Interestingly, aNOTCH signals were detected in recombinant and non-recombinant cells ([Figure S3C](#SD1){ref-type="supplementary-material"}), supporting the idea that cell autonomous and non-cell-autonomous effects occur downstream of *Nf1* mutation in mOLs ([@R39]).

Activation of Notch in mOLs Reduces Claudin 11 Expression and Causes Myelin Decompaction {#S7}
----------------------------------------------------------------------------------------

We investigated whether abnormal Notch activation in mOLs is sufficient to disrupt myelin compaction. We genetically activated Notch signaling in mOLs with the tamoxifen-inducible *RosaNICD* allele driven by *PlpCre*^ER^ (*pNICD*). One month post-tamoxifen treatment, myelin decompaction ([Figure 2G](#F2){ref-type="fig"}) and decreased g-ratio ([Figure S4A](#SD1){ref-type="supplementary-material"}) were found in *pNICD* animals, as compared to WTs. Decreased Claudin 11 corelates with myelin decompaction in *pNf1* mutants ([@R39]), and WB analysis showed a significant decrease of this TJ protein in the forebrain of *pNICD* mice ([Figure S4B](#SD1){ref-type="supplementary-material"}). Thus, genetic activation of Notch in mOLs mimics phenotypes caused by *Nf1* loss.

Notch Genetic Inhibition Rescues Myelin Decompaction in *Nf1* Mutants {#S8}
---------------------------------------------------------------------

RBPJ is a transcriptional co-factor required for canonical Notch signaling. To test whether increased canonical Notch signaling regulates phenotypes in *Nf1* mutants, we genetically inactivated Notch signaling in mOLs using *PlpCre*^ER^*;Nf1*^fl/+^(or *Nf1*^fl/f^)*;Rbpj*^fl/fl^ mice, in which *Rbpj* and *Nf1* are inactivated upon tamoxifen treatment. Unexpectedly, homozygous *Rbpj* inactivation in mOLs (*pRbpjf*/*f*) caused myelin decompaction 1 month post-tamoxifen treatment ([Figure 2H](#F2){ref-type="fig"}). Thus, imbalance in Notch signaling and/or compensatory responses affect myelin compaction in this genetic model. Importantly, hemizygous *Nf1* mutants with deletion of Rbpj (*pNf1f*/+*;Rbpjf*/*f*) showed full rescue of myelin decompaction ([Figure 2H](#F2){ref-type="fig"}) and g-ratio ([Figure S4C](#SD1){ref-type="supplementary-material"}) 6--8 months post-tamoxifen. Inactivation of *Rbpj* in *Nf1* homozygotes rescued g-ratio but did not significantly impact myelin decompaction 1 month post-tamoxifen; however, additional treatment of *pNf1f*/*f;Rbpjf*/*f* mice with MEKi fully rescued compaction to WT levels ([Figure 2H](#F2){ref-type="fig"}). Overall, these data indicate that Notch signaling is crucial for the maintenance of myelin structure in the WT setting and in the context of *Nf1* loss.

Gamma Secretase Inhibition Rescues Myelin Defects and Aberrant Behavior in *Nf1* Mutants {#S9}
----------------------------------------------------------------------------------------

To test whether *Nf1* loss-driven phenotypes can be rescued by pharmacological inhibition of Notch we used the blood-brain barrier-permeable gamma secretase inhibitor (GSI) MRK-003 ([@R15]). GSI administration to WT animals (weekly for 3 weeks) significantly decreased the number of Hes5GFP^+^ cells in the CC, confirming drug efficacy ([Figure 3A](#F3){ref-type="fig"}). Importantly, GSI treatment had no effect on myelin compaction in WT animals. In contrast, GSI treatment rescued decompaction ([Figure 3B](#F3){ref-type="fig"}) and g-ratio ([Figure S4D](#SD1){ref-type="supplementary-material"}) in *pNf1f*/+ animals 6--10 months post-tamoxifen. In fact, myelin compaction increased over WT levels, similar to the effect of MEKi ([Figure 1C](#F1){ref-type="fig"}). In *Nf1* homozygous mutants GSI significantly increased g-ratio ([Figure S4D](#SD1){ref-type="supplementary-material"}), however, no significant changes in myelin decompaction were observed. These data suggest that GSI treatment normalizes the unbalanced Notch signaling that promotes decompaction in *Nf1* mutants.

NF1 patients display mutation/loss of 1 *NF1* allele and present locomotor, cognitive and attention issues. We therefore tested whether behavior is altered in hemizygous *pNf1* mutants. We evaluated sensory gating deficits in *Nf1* hemizygous mutant mice (C57BL/6 genetic background), by analyzing the prepulse inhibition of startle response ([@R53]), 9 months post-tamoxifen treatment. Significantly heightened response to startle at 73--82 dB, was found in *pNf1* mutants as compared to controls ([Figure 3C](#F3){ref-type="fig"}). Remarkably, all increased startle responses (73--82 dB) were blocked by treatment with GSI for 3 weeks, as compared to littermate WTs ([Figure 3D](#F3){ref-type="fig"}). Thus, hemizygous *Nf1* mutation in mOLs causes myelin structural defects and behavioral abnormalities that can be rescued by pharmacological inhibition of Notch signaling.

Notch Activation and Myelin Decompaction Are Due to Increased Nitric Oxide Signaling in *Nf1* Mutants {#S10}
-----------------------------------------------------------------------------------------------------

*Nf1* loss in oligodendrocytes was reported to result in increased reactive oxygen/nitrogen species in the forebrain, and treatment with the antioxidant N-acetyl cysteine rescued cell-autonomous and non-cell-autonomous defects in the ON of *pNf1* mutants ([@R39]). To test whether mOL NO contributes to CC myelin abnormalities, *Nf1* mutants were treated with a specific inhibitor of NO synthases L-NAME (N-nitroarginine methyl ester, 0.4 mg/kg) for 7 days, starting after severe decompaction is detectable. L-NAME treatment fully rescued myelin compaction ([Figure 4A](#F4){ref-type="fig"}) and g-ratio ([Figure S4F](#SD1){ref-type="supplementary-material"}) in *pNf1f*/+ mutants. In *pNf1f*/*f* mice, treatment significantly increased g-ratio, but did not rescue compaction to WT levels. Notably, full rescue of de-compaction in the homozygous mutants required inhibiting both Notch and NO signaling (Rbpj deletion and L-NAME treatment) or MAPK and NO signaling (MEKi and L-NAME treatment) ([Figures 4A](#F4){ref-type="fig"} and [S4F](#SD1){ref-type="supplementary-material"}).

We therefore tested whether elevated NO levels drive Notch activation ([@R11]; [@R32]) in *Nf1* mutants or whether Notch activation is an independent *Nf1*-driven signal in mOLs. L-NAME treatment for 7 days rescued the abnormally increased number of aNotch^+^;CC1^+^/CC1^+^ mOLs in the CC of *pNf1f*/*f* mutants, as compared to L-NAME-treated WT mice ([Figures 4B and 4C](#F4){ref-type="fig"}). Thus, abnormally increased Notch signaling in mOL is reduced by NOS inhibition. Flow cytometry analysis of forebrain showed that neither NO nor superoxide signals changed in Hes5GFP^+^ cells of *pNf1f*/*f* mutants, versus Hes5^+^ cells in WT animals ([Figure S4E](#SD1){ref-type="supplementary-material"}). Demonstrating that Notch does not drive NO, overexpression of NICD in mOLs (*PlpCre*^ER^*;RosaNICD*) did not alter numbers of NO^+^GalC^+^ cells, and NO^+^ cells remained unchanged in *Nf1* mutants with genetic inactivation of canonical Notch signaling as compared to *pNf1f*/*f* mutants ([Figures 4D and 4E](#F4){ref-type="fig"}). A linear MAPK/NO/Notch pathway downstream *Nf1* loss might explain why single agent treatments fully rescue myelin decompaction in hemizygous *pNf1* mutants. However, combined inhibition of MAPK, NO, and Notch signaling ([Figures 2H](#F2){ref-type="fig"} and [4A](#F4){ref-type="fig"}) is necessary to normalize effects in homozygous mutants plausibly because of a more robust pathway activation; durable feedback loops may also explain this finding.

*Nf1* Loss and Oligodendrocyte Numbers {#S11}
--------------------------------------

*Nf1* loss in mOLs was found to increase numbers of Olig2^+^ cells in the CC 4 days after tamoxifen treatment ([@R39]). To test if this increase is durable, we quantified CC Olig2^+^ cells 1 month post-tamoxifen. Olig2^+^ cells were not significantly increased in *pNf1f*/*f* mutants versus WT ([Figures S6A and S6B](#SD1){ref-type="supplementary-material"}). As Olig2 labels all oligodendrocyte lineage cells, we identified by flow cytometry-specific forebrain cell populations using the markers PDGFRα, O4, and GalC. mOLs (PDGFRα^−^ GalC^+^ or O4^−^GalC^+^) did not show altered numbers in *pNf1* mutants. Therefore, overall changes in numbers of oligodendrocytes are unlikely to account for our findings. We note that maturing OLs (PDGFRα^+^GalC^+^) were significantly increased in *pNf1f*/*f* animals ([Figure S6C](#SD1){ref-type="supplementary-material"}), and within the Hes5^+^ population, O4^+^GalC^+^ cells were also significantly increased ([Figure S6D](#SD1){ref-type="supplementary-material"}). Non-cell-autonomous effects on oligodendrocyte progenitors and/or re-expression of immature OL markers in GalC^+^ mOL might explain these phenotypes.

*Nf1*^+/−^Mice Show Increased Notch Activity, and NF1 Patients Show Hyperactivated Notch {#S12}
----------------------------------------------------------------------------------------

To determine whether control of myelin compaction through Notch signaling might be relevant to NF1 patients, we first evaluated Notch activation in the brain of *Nf1*^+/−^mice, which mimic NF1 patients genotype with germline mutation in one *Nf1* allele in all brain cells. Notch activation was elevated in *Nf1*^+/−^mutants, as in the Notch-activity reporter mouse *Nf1*^+/−^;*Hes5GFP*, numbers of Hes5GFP^+^ cells in CC were significantly increased, as compared to WT animals ([Figures 5A and 5B](#F5){ref-type="fig"}).

Finally, we used two antibodies to detect cells with activated Notch^+^ (aNOTCH or NICD) in brain sections from previously described adult NF1 patients ([@R43]). Both antibodies (ab8925 and cs2421) detected higher number of NICD^+^ cells in the subcortical WM of NF1 patients (n = 2), as compared to normal adult brain (n = 2) ([Figures 5C](#F5){ref-type="fig"} and [S5A](#SD1){ref-type="supplementary-material"}). Quantification of two technical replicates (reflecting experimental variability, not the variability of the biological process), showed significantly increased number of aNOTCH^+^ cells ([Figure 5D](#F5){ref-type="fig"}). To address the issue of precisely matching brain regions in the limited specimens available, we normalized the percentage of aNOTCH^+^ cells to the total number of cells per field and found similar results ([Figure 5E](#F5){ref-type="fig"}). Overall, our data are consistent with the idea that abnormal Notch signaling downstream of *Nf1* loss and NO increase contribute to NF1 patient pathology.

DISCUSSION {#S13}
==========

The study of WM abnormalities that correlate with motor, sensory, or cognitive changes in pathological situations may help to identify mechanisms relevant to normal brain function. We focused on brain pathology in NF1, a common genetic disorder in which patients show WM disorganization on brain imaging, and neurological deficits. We show that Notch signaling, along with MAPK and NO, are aberrantly activated after *Nf1* loss in mature oligodendrocytes, causing myelin decompaction and changing animal behavior.

Patient mutations in genes throughout the RAS-MAPK pathway (Rasopathy genes) compromise brain function ([@R46]). *Nf1* is a well-studied Rasopathy gene that acts as a regulator of RAS-MAPK signaling ([@R21]; [@R45]). Increasing evidence confirms a role for MAPK activation in NF1 brain. For example, abnormally enlarged CC resulting from *Nf1* loss is rescued by perinatal MEK inhibition ([@R54]). In oligodendrocyte progenitors with *Nf1* mutation, basal and FGF-stimulated RAS-GTP are increased, proliferation increases, and differentiation is aberrant, although myelination occurs ([@R6]). In contrast to these developmental studies, our analyses ensue after deletion of *Nf1* in mature cells. Our results are encouraging as they support the idea that alterations in NF1 brain may be susceptible both to prevention and to therapy.

Myelin decompaction resulting from *Nf1* loss in oligodendrocytes accounts for pathological increases in myelin thickness, as numbers of myelin lamellae did not significantly change. This result differs from studies in which the RAS effector proteins ERK1/2 regulate myelin thickness by increasing numbers of myelin wraps ([@R29]), as assessed using gain and loss-of-function models. In our model, after *Nf1* loss, RAS, MEK, and ERK proteins are present at normal levels; therefore, extrinsic stimuli activate transient signaling through MEK/ERK. The transience of the RAS signal after *Nf1* loss likely accounts for the discrepancy with studies of constitutive activation or complete loss of ERK. Other RAS effector pathways activated by loss of *Nf1* may also contribute to decompaction after homozygous *Nf1* loss, although this seems less likely given that MEK inhibition alone blocks decompaction after hemizygous *Nf1* loss.

Increased Notch signaling following *Nf1* loss was demonstrated by microarray/RNA-seq analyses and corroborated by in vivo detection of NICD in CC1^+^ mOLs. Cell-autonomous roles of oligodendrocyte Notch in controlling myelin compaction are supported by our genetic gain- (NICD) and loss-of-function (Rbpj) models. Furthermore, although GSI can have effects on other substrates, our finding that GSI rescues aberrant myelin decompaction is consistent with our detection of active nuclear NICD in oligodendrocytes and the genetic data indicating that Notch blockade via Rbpj loss reverses effects of *Nf1* loss. The correlation between rescued decompaction and GSI rescue of abnormal startle response in *pNf1* mutants suggests that myelin compaction is relevant to normal behavior. Importantly, GSI treatment did not affect WT myelin structure or behavior in our study. It will be of great interest to define a direct link between abnormal activation of Notch with decompaction and behavior in animal models and whether increased activation of Notch in NF1 patients is linked to their neurological issues.

Notch, via Hes5, regulates many processes in immature oligodendrocyte lineage cells ([@R38]; [@R55]). We found that Hes5 transcript is increased in a *Nf1* mutant glial precursor-enriched population in vitro, and NICD and Hes1/5 increases were recently reported downstream of *Nf1* inactivation in neural stem cells ([@R13]). However, it is likely that Notch effector-driven cell-autonomous effects on mOL do not require Hes5, in that CC1^+^Hes5^+^ are rare (albeit increased) in *Nf1* mutants and do not show detectable ERK activation. It remains possible that in *Nf1* mutants, Hes5^+^ cells and/or an increased population of O4^+^GalC^+^ maturing oligodendrocytes, contribute to abnormal myelin compaction. However, the broad expression of mOL NotchICD in the absence of Hes5 strongly suggests the pathological relevance of alternate Notch effector proteins in this setting.

We previously reported that *Nf1* mutation in oligodendrocytes causes small but significant increase in NO levels in the forebrain ([@R39]). Here, we extend the results to CC oligodendrocytes and demonstrate that increased NO is upstream of Notch-mediated myelin decompaction. In oligodendrocytes, NO is protective at low levels, while at high levels causes ERK1/2-mediated toxicity ([@R37]) and downregulation of myelin genes preceding cell death ([@R31]). Also at low concentrations, NO induces cGMP-mediated morphological changes ([@R25]). As no increased mOL cell death was found in *pNf1* mice ([@R39]), it is probable that NO does not accumulate to lethal levels after Nf1 loss. Yet, myelin structural defects develop in an *Nf1* gene-dose-dependent manner. We propose that the slow progression of myelin decompaction in hemizygous *Nf1* mutants is caused by modest increased MAPK and downstream signals that causes cumulative damage, while biallelic loss of *Nf1* causes higher levels of pathway activation and more rapid decompaction. Other *Nf1* gene-dose-dependent phenotypes have been reported. For example, *Nf1* hemizygous oligodendrocyte precursors are expanded in vitro, to a lesser extent than *Nf1* homozygous mutant cells ([@R6]). Only *Nf1*^−/−^ sympathetic neurons develop neurites independent of growth factor ([@R52]), but *Nf1*^+/−^ mice show defects in Morris water maze tests and dopamine-based learning ([@R3]).

It is well known that RAS-GTP signaling can act up or downstream of Notch and have a cooperative or antagonistic outcomes ([@R49]). In fact, multilineage differentiation of neural stem cells is controlled by *Nf1* via RAF/MEK pathway and Notch activation ([@R13]), however, the link between these signal pathways is unclear. We find that increased active Notch is rescued by L-NAME treatment, suggesting that NO is a mediator between RAS-Nocth signaling in *Nf1* mutants. Thus, a linear MAPK/NO/Notch pathway might drive myelin de-compaction and behavioral phenotypes in hemizygous mutants ([Figure 6A](#F6){ref-type="fig"}). In support of this idea, single agent treatment with MEKi ([Figure 1C](#F1){ref-type="fig"}), GSI ([Figure 3B](#F3){ref-type="fig"}), or L-NAME ([Figure 4A](#F4){ref-type="fig"}) fully rescue myelin decompaction, and GSI alone rescues behavioral abnormalities. Similar pathway interactions have been reported in PDGF-induced gliomas, in which NO/cGMP/PKG ([@R11]) or NO/ID4/Jagged1 ([@R32]) signaling drive Notch activation and tumor growth.

A linear MAPK/NO/Notch pathway, however, does not easily explain why blocking each pathway alone does not rescue decompaction in homozygous mutants. A parsimonious explanation is that the more robust activation of RAS in *pNf1f*/*f* mutants requires longer treatments with single drugs, higher doses, or combinations of drugs, to fully diminish the effects of RAS over activation ([Figure 6B](#F6){ref-type="fig"}). Alternatively, increased MAPK, NO, and Notch signaling might cause durable transcriptional or posttranscriptional changes that feedback and potentiate the effects of the entire pathway. In support of this idea, NOS1-3 proteins are increased in *pNf1* homozygous mutants ([@R39]). Given that oligodendrocytes express NOS1 ([@R56]) and possibly NOS2 ([@R7]), transcriptional regulation of these and other genes involved in the pathway is conceivable. The specific Notch effector(s) controlling myelin compaction remain unknown. Myelin proteins regulating compaction, including Claudin 11, might be involved. We found that genetic activation of Notch decreases Claudin 11. Of note, mice with loss of the *Plp1* and *Cldn11* show impaired motor behavior and myelin decompaction, similar to those found in *pNf1* mutants ([@R14]). Regulation of *Cldn11* by Notch has not been reported, and in silico analysis do not show binding sites for CSL/Rbpj (<http://genome.ucsc.edu>). However, a binding site for PU.1, a transcription factor regulated by Notch ([@R12]) and downregulated in *pNf1* mutants, is upstream of *Cldn11*. Additional downregulation of TJ/GJ genes (*Tjp2*, *Gjb6*, *Gjb2*) may also contribute to abnormal myelin and behavior ([Figure 6](#F6){ref-type="fig"}).

Most myelinated fibers in *Nf1* mutants showed decompaction, even though deletion of *Nf1* occurs in a smaller number of mOLs ([@R34]; [@R39]). This result suggests that a diffusible messenger signals to non-recombinant cells. Diverse paracrine roles of NO have been widely reported in the brain ([@R10]), thus, NO could mediate effects to neighbor cells in *pNf1* mutants ([Figure 6](#F6){ref-type="fig"}). In fact, several non-cell-autonomous defects are detected after deletion of *Nf1* in mOLs ([@R39]).

In summary, activation of Notch signaling, downstream of MAPK and NO, results in myelin decompaction and behavioral changes in *Nf1* hemizygous mutants. It is believed that most cells in NF1 patient brains contain one normal *NF1* allele and one mutant/lost allele of the *NF1* gene. However, there are brain regions with especially poor organization that may represent regions of biallelic *NF1* loss, based on DTI ([@R22]). If biallelic *NF1* mutations are present in oligodendrocytes in NF1 patient brains and cause WM alteration ([@R22]; [@R33]), drug combinations might be needed therapeutically. Importantly, our findings that NO/Notch signaling is perturbed in *Nf1*^+/−^ mice, and that NICD increases in NF1 patients raise the intriguing possibility that the pathways we identified in mouse mOLs will be relevant to NF1 patients. Based on these studies, drugs that block the *Nf1* loss-dependent increased NO and subsequent Notch activation should be considered to treat disease manifestations in NF1.

EXPERIMENTAL PROCEDURES {#S14}
=======================

Mouse Strains {#S15}
-------------

All mouse studies were approved by the Cincinnati Children's Hospital Research Foundation Institutional Animal Care and Use Review Committee (IACUC). The generation and genotyping of mice carrying *Nf1*^fl/fl^ \[Nf1tm1Par/J\] ([@R57]), *PlpCre* \[B6.Cg-Tg(Plp1-Cre/ERT)3Pop/J\] ([@R20]), *Hes5*-GFP \[Tg1(Hes5GFP)Gsat/Mmmh\] ([@R26]), Rbpj^fl/fl^ \[RBP-J^f/f^\] ([@R27]), *RosaNICD* \[Gt(ROSA)26Sortm1(Notch1)DAM/J\] ([@R42]), and Nf1^+/−^ ([@R8]) alleles, are described in previous studies. Mice were maintained on the C57BL/6 background. For behavioral studies, only adult female mice were used. In all other studies, we used adult mice of both sexes. Mice were housed in a temperature- and humidity-controlled vivarium on a 12 hr light-dark cycle with free access to food and water.

Pre-clinical Therapeutics {#S16}
-------------------------

Gamma secretase inhibitor (GSI,MRK-003; Merck) was made fresh weekly and dosed at 300 mg/kg in 0.5% methocel by oral gavage ([@R35]; [@R47]). For pathology, we dosed mice once weekly for 4 weeks and sacrificed 6 hr after the last dose (n = 5 doses). For flow analysis, we dosed mice once weekly for 1 week and sacrificed mice 6 hr after the last dose (n = 2 doses). Fresh solution of L-NAME (L-NG-nitroarginine methyl ester, 100 μM in 1× PBS; Sigma-Aldrich) was administered daily at 0.4 mg/kg. For pathology and flow analysis, mice were injected intraperitoneally (i.p.) daily for 7 days and sacrificed 6 hr after the last dose. MEK inhibitor (PD0325901; Pfizer) was made fresh weekly and dosed at 1.5 mg/kg/day in 0.5% methocel/0.2% Tween 80, by oral gavage. For pathology, we dosed mice every day for 3 weeks. For flow analysis, we dosed mice every day for 7 days and sacrificed 6 hr after the last dose.

Behavior {#S17}
--------

Behavioral assessments were completed on *pNf1fl*/+ mice (F12, backcrossed onto C57BL/6) mice. Acoustic startle response, with prepulse inhibition, was assessed as described ([@R53]). White noise background of 70 dB, prepulses of 73, 77, and 82 dB, and a mixed frequency startle stimulus of 120 dB were used. Animals received 100 trials per day with equal numbers of trials using a Latin square design that was duplicated. Animals were tested on 2 consecutive days and the data from the second day were analyzed, because animals that are tested on a single day for the acoustic startle response tend to have greater variability that can mask group differences.

Human Brain Tissues {#S18}
-------------------

Brain specimens were described previously ([@R43]). Briefly, NFI brains were obtained from patients diagnosed with NF1 based on NIH guidelines. None of these patients showed any evidence of neurological disease other than NF1. Control/normal brains were obtained from adult patients with no neurological diseases reported, although a history of depression was reported in one. All brains were harvested within 8 hr after death. Brains were sliced and placed in 4% paraformaldehyde/0.1 M phosphate buffer for 72 hr and prepared for paraffin embedding and storage.

Statistical Analysis {#S19}
--------------------

The minimal number of animals per statistically significant experiment was three. Comparison between two groups used Student's t tests with a significance cutoff of p \< 0.05. Comparison of three or more groups used the one-way ANOVA, followed by Tukey post hoc test with a significance cutoff of p \< 0.05. For unbiased counting of myelinated axons, mice were randomized and treated in a blinded manner. For behavior, acoustic startle was analyzed by mixed linear Two-way ANOVA with factors of genotype and trial. Further comparisons averaged across interval, day, and trial for genotype differences were compared by (two-tailed) t test for independent samples.
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======================
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![Progressive Myelin Decompaction Regulated by MAPK Signaling in *pNf1* Mutants\
(A and B) Electron micrographs of the corpus callosum (CC) of WT, *pNf1f*/+, and *pNf1f*/*f* mice show regions of myelin decompaction (A, arrows; B, purple) at the indicated months (mo) post-tamoxifen treatment. Insets: regions from dotted rectangles (50,000×). Number of myelin wraps (triangles) in WT and *pNf1f*/*f* mutants are shown in (B).\
(C) The percent of decompacted fibers among total fibers and number of quadrants with decompaction (color code) in the short-term (ST; 1 month) and long-term (LT; 6--10 months) post-tamoxifen is shown. Significantly increased decompaction is found in *pNf1f*/*f* mice at ST (n = 5 mice,\*\*p \< 0.01), and in *pNf1f*/+ mice at LT (n = 3 mice,\*p \< 0.05), as compared to WT (ST-LT, n = 6 mice). Moderate (1--3 quadrants), but not significant (ns), decompaction is observed in *pNf1f*/+ mice at ST (n = 3 mice). MEKi treatment rescues decompaction in *pNf1f*/+ mutants (n = 3 mice, \*p \< 0.05) but does not change decompaction in *pNf1f*/*f* mutants (n = 3 mice). Data are presented as the mean + SEM. One-way ANOVA; p = 0.0005, and Tukey's multiple comparisons test.\
(D) Immunostaining of pERK (red) and CC1 (white) in the CC of the indicated genotypes. Magnifications of squared regions (left) depict a pERK^+^;CC1^−^ cell in WT (nuclear signal, arrowhead), pERK^+^(faint);CC1^+^ mOLs (yellow arrows) in *pNf1f*/+, and pERK^+^(strong);CC1^+^ mOLs in *pNf1f*/*f* mice. LV, lateral ventricle. Scale bar, 10 μm.\
(E) Significantly increased pERK^+^;CC1^+^/total CC1^+^ mOLs are found in *pNf1f*/*f* mice as compared to WT (n = 4 mice/genotype, t test;\*\*p = 0.0053, data are the mean + SEM).\
See also [Figures S1 and S2](#SD1){ref-type="supplementary-material"}.](nihms944481f1){#F1}

![Increased Notch Pathway Activity in mOLs Causes Myelin Decompaction in *pNf1* Mutants\
(A) Data from microarray analysis and qRT-PCR validation show increased expression of genes in Nf1^−^/^−^ glial-enriched cultures (t test, Hes5\*\*\*\*p \< 0.0001; Dll1\*\*p = 0.0055, Dll3\*\*p = 0.004, n = 3 cultures).\
(B) Western blot analysis of Notch1 and Ras10 (loading control) indicates increased activated Notch 1 (97 kD) in Nf1^−/−^ glia-enriched cultures.\
(C) RNA-seq analysis of *pNf1f*/*f* ON 1 month post-tamoxifen. Heatmap showing gene expression levels (log2 fold change) and p values for genes of canonical and non-canonical Notch ligands (*Dll1*, *Dlk2*, *Dner*, *Cntn1*, *Thbs2*, *Postn*, *Jag1*), Notch targets (*Hes5*, *Cntnap2*, *Cttnbp2*, *Spi1*), tight junctions (*Cldn11*, *Tjp2*), and GAP junctions (*Gjb6*, *Gjb2*). Expression of *Mbp*, *Plp1*, *Mag*, *Mog*, and *Omg* did not show significant changes (n = 3/genotype, DESeq normalization method).\
(D) Immunofluorescence of Hes5GFP (green), aNOTCH (red), and CC1 (white) 1 month post-tamoxifen. In magnification (right) of squared regions: Hes5GFP (yellow arrows) is detected in rare CC1^+^ (weak) mOLs, aNOTCH (arrowheads) is detected in cytoplasm of mOLs in WT (*Hes5GFP*) and nuclei of abundant mOLs in *pNf1f*/*f;Hes5GFP* mutant (pink, bottom/right). CC, corpus callosum; LV, lateral ventricle. Scale bar, 10 μm.\
(E) The percent of Hes5GFP^+^;CC1^+^/CC1^+^ cells significantly increases in *pNf1f*/*f* mutants as compared to WT (n = 4 mice/genotype, t test; \*\*p = 0.0013). Inset: y axis enlargement.\
(F) The percent of aNOTCH^+^;CC1^+^/CC1^+^ cells significantly increases in *pNf1f*/*f* mutants (n = 7 mice) as compared to WT (n = 4 mice, t test; \*\*\*p = 0.001). Data are the mean + SEM.\
(G and H) Percent of decompacted fibers and severity of decompaction (quadrants) in the indicated genotypes in the short- (1 month) or long-term (6--9 months) post-tamoxifen. Increased decompaction is shown in *PlpCre;RosaNICD* (G, n = 4 mice, t test, \*\*\*p \< 0.0001), and *pRbpjf*/*f* (H, n = 3 mice, \*p \< 0.01) as compared to WTs (n = 6 mice). Note that decompaction is not rescued in *pNf1f*/*f;Rbpjf*/*f* (versus *pNf1f*/*f*), but it is rescued by additional treatment with MEKi (n = 3, \*\*p \< 0.001, one-way ANOVA). Decompaction is fully rescued in *pNf1f*/+;*Rbpjf*/*f* mutants (versus *pNf1 f*/+, n = 3 mice/genotype, \*p \< 0.01 one-way ANOVA).\
Error bars show ± SEM. See also [Figures S3 and S4](#SD1){ref-type="supplementary-material"}.](nihms944481f2){#F2}

![Pharmacological Inhibition of Notch Activation in *pNf1* Mutants Rescues Decompaction and Aberrant Behavior\
(A) Number of Hes5GFP^+^ cells in the CC of vehicle-treated (n = 5 mice) or gamma secretase inhibitor (GSI)-treated (n = 12 mice) WT mice (t test, \*p = 0.0001).\
(B) The percent of decompacted fibers and quadrants with decompaction does not change after GSI treatment in WT animals (n = 6 vehicle-treated, n = 4 GSI-treated animals, t test, ns, p = 0.4516) and *pNf1f*/*f* mutants (n = 5 mice/genotype, ns, p = 0.2768). Decompaction is rescued in *pNf1f*/+ mice treated with GSI (n = 4 mice, t test, \*\*p = 0.0019) as compared to vehicle-treated *pNf1f*/+ (n = 3). ST, 1 month post-tamoxifen; LT, 6--10 months post-tamoxifen.\
(C and D) Evaluation of the acoustic startle response. (C) *pNf1f*/+ mutant mice (n = 21 mice) present increased V~max~ to the acoustic startle response following the 73 dB, 77 dB, and 82 dB pre-pulse stimuli, as compared to WT mice (n = 19 mice, two-way ANOVA, F\[4,152\] = 3.05, \*p \< 0.05). (D) The heightened startle response in *pNf1f*/+ mutants is abolished after treatment with GSI MRK-003, as no significant difference in V~max~ is observed between WT (n = 21 mice) and *pNf1* mutants (n = 19 mice, two-way ANOVA, F\[4,152\] = 2.73).\
Error bars show ± SEM. See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms944481f3){#F3}

![NO Controls Notch Activation and Concomitant Inhibition of Notch/NO or NO/MAPK Signaling Rescues Decompaction in *pNf1f*/*f* Mutants\
(A) Decompacted fibers (%) and quadrants with decompaction in mice treated with L-NAME (7 days) and MEKi (21 days). L-NAME treatment rescues myelin compaction in the long-term (LT) *pNf1f*/+ mice (n = 4 mice/treatment, \*\*p \< 0.01). Note that % of decompacted fibers does not significantly change in L-NAME-treated *pNf1f*/*f* mice (ST, short-term), but decompaction is fully rescued in L-NAME-treated *pNf1f*/*f;Rbpjf*/*f* (n = 3 mice, \*p \< 0.05), or in L-NAME;MEKi-treated *pNf1f*/*f* (n = 3 mice, \*\*p \< 0.01), as compared to *pNf1f*/*f* mice.\
(B) Immunostaining of aNOTCH (red) and CC1 (white) in the CC of vehicle- or L-NAME-treated WTs and *pNf1f*/*f* mutants. Note the lower number of aNOTCH^+^;CC1^+^ cells in L-NAME-treated *pNf1f*/*f* mutants, as compared to untreated mutants. Scale bar, 10 μm.\
(C) WT and *pNf1f*/*f* mice show no significantly different numbers of aNOTCH^+^;CC1^+^ mOLs (yellow arrows in B) after L-NAME treatment (n = 3 mice/genotype, t test, p = 0.9721). Untreated animals (from [Figure 2F](#F2){ref-type="fig"}) are shown for comparison.\
(D) Flow cytometry analysis of forebrain cells indicates that the number of GalC^+^ mOLs showing NO signals does not change in *PlpCreER;RosaNICD* (*pNICD*) mice, as compared to WT animals (n = 3 mice/genotype, t test, p = 0.86).\
(E) Flow cytometry analysis of forebrain cells indicates that the number of GalC^+^ mOLs showing NO signals does not change in *pNf1f*/*f;pRbpjf*/*f* mice as compared to *pNf1f*/*f* mutants (n = 3 mice/genotype, t test, p = 0.29).\
Error bars show ± SEM. See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms944481f4){#F4}

![Notch Signaling Increases in *Nf1^+^*^/−^ mice, and aNotch^+^ Cells Are Increased in NF1 Patient WM\
(A and B) The number of Hes5GFP^+^ cells in the CC (A) of *Nf1^+^*^/−^ mice is significantly increased (B), as compared to WT animals (n = 3 mice/genotype, t test, \*\*\*p = 0.0004).\
(C) Immunodetection of NICD (aNOTCH) with a specific antibody (Cell Signaling, cs2421) in the subcortical WM (scWM) of NF1 patient brains (n = 2) and normal human brains (n = 2). Representative aNOTCH nuclear signals are shown with red arrows (insets). Scale bars, 50 μm.\
(D) Quantification of total aNOTCH^+^ cells per 20× field suggests increased Notch activity in the scWM of NF1 patients, as compared to normal brain (n = 2 NF1 patients, n = 2 normal brains, 2 technical replicates/condition, t test, \*\*p = 0.0042).\
(E) Quantification of aNOTCH^+^ cells as percent of total cells per 20× field supports increased Notch activity in the scWM of NF1 patients, as compared to normal brain (n = 2 NF1 patients, n = 2 normal brains, 2 technical replicates/condition, t test, \*\*\*p = 0.0014). Error and significance of the graphs reflect only experimental variability.\
Error bars show ± SEM. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms944481f5){#F5}

![Model of *Nf1* Loss-Driven Myelin Decompaction\
Increased MAPK/NO/Notch signaling may mediate myelin decompaction (gray-dotted arrows and insets), by downregulation of TJ/GJ proteins involved in myelin compaction such as Claudin 11 (*Cldn11*), ZO-2 (Tjp2), and Connexin 26 (*Gjb2*) in *pNf1* mutants.\
(A) Decreased Nf1 (blue) results in increased RAS-GTP in mature oligodendrocytes, leading to hyperactive MAPK signaling (RTK →RAS →pMEK →pERK). Production of NO increases in response to hyperactive MAPK pathway (NOS, dashed arrow). Subsequently, NO promotes directly or indirectly (dotted line) Notch cleavage and translocation of NICD to the nucleus, where it regulates gene expression. Furthermore, diffusion of NO from *Nf1* mutant oligodendrocytes (white arrows) might affect nearby oligodendrocytes increasing the number of decompacted fibers (bottom). Either pharmacological treatment alone (MEKi, L-NAME or GSI) rescues decompaction (purple lines).\
(B) Absent Nf1 (red) results in accumulation of RAS-GTP and stronger induction (thick arrows) of MAPK signaling and NO production. It is possible that long-lasting transcriptional and/or post-transcriptional changes (dotted lines with question marks) in molecules controlling NO levels (for example NOS1-2) might contribute to increases in NO. Subsequently, NO promotes Notch activation and regulation of myelin genes. Combination of inhibitors (MEKi and L-NAME, purple fused lines) rescues decompaction, while single agent treatments (for example GSI, fading purple arrow) improves severity but does not rescue decompaction. Note that genetic inactivation of Notch ([Figure 5](#F5){ref-type="fig"}) combined with MEKi or L-NAME, also rescues compaction in this setting.](nihms944481f6){#F6}

###### Highlights

-   Experimental oligodendrocyte *Nf1* inactivation causes myelin and behavioral defects

-   Hyper-active Notch in oligodendrocytes is necessary and sufficient to disrupt myelin

-   Pharmacological inhibition of Notch normalizes myelin and behavior in *Nf1* mutants

-   Nf1^+/−^ mouse and patient brains suggest Notch hyper-activation in NF1 pathogenesis
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